Cognito Therapeutics vs Tempus
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $105M oversubscribed Series C (Mar 2026) led by Morningside Ventures. HOPE pivotal trial fully enrolled. Non-pharmacological Alzheimer's device targeting FDA clearance.
About
Cognito Therapeutics is developing a non-pharmacological treatment for Alzheimer's disease using coordinated gamma-frequency light and sound stimulation — a technology called sensory entrainment that modulates neural oscillations implicated in the disease. The company raised an oversubscribed $105 million Series C in March 2026 led by Morningside Ventures, with its pivotal HOPE clinical trial fully enrolled and topline data expected in late 2026.
Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.
About
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.